Sort
48,018 grants matching “immunotherapy”
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma
$734,238Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Pathogenesis and Treatment of Anaphylaxis
$734,162Dean D Metcalfe · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors
$734,126Christopher C. Derenzo · St. Jude Children'S Research Hospital · R01 · FY2022 · CA
Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision Medicine
$733,862Obi L. Griffith · Washington University · U24 · FY2021 · CA
Quantifying the fitness cost of HIV-1 resistance to broadly neutralizing antibodies
$733,848Rebecca Marie Lynch · George Washington University · R01 · FY2020 · AI
Depletion, Repopulation and Tolerance in Sensitized Recipients
$733,697Stuart Johnston Knechtle · Duke University · U19 · FY2022 · AI
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
$733,631James Even Voss · Scripps Research Institute, The · R01 · FY2024 · AI
ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection
$733,555Yi Zhang · Hackensack University Medical Center · R01 · FY2025 · CA
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
$733,308Mark Yarchoan · Johns Hopkins University · R01 · FY2022 · CA
Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity
$733,069Hao Wu · Boston Children'S Hospital · R01 · FY2025 · CA
Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity
$733,069Hao Wu · Boston Children'S Hospital · R01 · FY2024 · CA
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients
$733,032Zhongxing Liao · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · HL
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
$732,973Andre Rogatko · Cedars-Sinai Medical Center · U01 · FY2018 · CA
Allergen Loaded Nanoparticles for Food Allergy Tolerance
$732,841Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2024 · AI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH
$732,720Marlene Rabinovitch · Stanford University · R01 · FY2018 · HL
The COVID-19 and Cancer Consortium (CCC19) Registry
$732,687Jeremy Lyle Warner · Rhode Island Hospital · U01 · FY2024 · CA
bZIP proteins, NFAT, and lymphocyte gene induction
$732,684Anjana Rao · La Jolla Institute For Immunology · R01 · FY2017 · AI
bZIP proteins, NFAT, and lymphocyte gene induction
$732,684Anjana Rao · La Jolla Institute For Immunology · R01 · FY2015 · AI
bZIP proteins, NFAT, and lymphocyte gene induction
$732,684Anjana Rao · La Jolla Institute For Immunology · R01 · FY2016 · AI
bZIP proteins, NFAT, and lymphocyte gene induction
$732,684Anjana Rao · La Jolla Institute For Immunology · R01 · FY2018 · AI
Clinical Implications of Natural Killer-derived exosomal miRNAs in Neuroblastoma
$732,471Muller Fabbri · Children'S Research Institute · R01 · FY2025 · CA
Immune Dysregulation During Multiple Sclerosis Relapse
$732,451Nitin J Karandikar · University Of Iowa · R01 · FY2017 · AI
Immune Dysregulation During Multiple Sclerosis Relapse
$732,451Nitin J Karandikar · University Of Iowa · R01 · FY2019 · AI
Immune Dysregulation During Multiple Sclerosis Relapse
$732,451Nitin J Karandikar · University Of Iowa · R01 · FY2020 · AI
ViKTriY-PC Consortium Phase II Supplement
$732,368Patricia M Lorusso · Yale University · UM1 · FY2016 · CA